No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo’s business, particularly those mentioned in the risk factors and cautionary statements in Sucampo’s Form 10-K for the year ended Dec. 31, 2011, which the Company incorporates by reference.
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of preclinical data at Digestive Disease Week 2012, in San Diego, which demonstrates the protective effect of cobiprostone (also known as SPI-8811) against epithelial barrier dysfunction in models of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury. The poster entitled, “The Protective Effect of ClC-2 Agonist SPI-8811 on Indomethacin-induced Epithelial Barrier Dysfunction in Human Gastric Epithelial Cells,” was authored by Meghali Nighot and Anthony Blikslager, of NC State University College of Veterinary Medicine, and Ryuji Ueno, of Sucampo. In the study presented, treatment with the NSAID indomethacin resulted in increased permeability due to dysregulation of occludin co-localization. The results of this in vitro study show that cobiprostone, via ClC-2 activation, can counter act such adverse effects of NSAID on tight junction proteins. Additionally, cobiprostone was shown to prevent indomethacin-induced cell death. “NSAIDs are commonly prescribed drugs for pain, fever and inflammation, but are not ideal for long-term use because of the risk of ulcer formation,” said Anthony Blikslager, DVM, Ph.D., DACVS, NC State University, College of Veterinary Medicine. “In this study, we demonstrated that cobiprostone exerts a protective effect against epithelial barrier dysfunction in the presence of an NSAID in human gastric epithelial cells. Based on these data, we believe that cobiprostone could serve as a treatment option in patients taking NSAIDs.” About cobiprostone Cobiprostone is an investigational prostone compound under development by Sucampo Pharmaceuticals Inc. as a potential treatment for gastrointestinal, liver and respiratory diseases. Sucampo holds worldwide, exclusive rights to cobiprostone. About Sucampo Pharmaceuticals Sucampo Pharmaceuticals, Inc., an international pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com. Sucampo Forward-Looking Statements This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo’s ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.